Advertisement

Drugs

, Volume 34, Supplement 1, pp 62–70 | Cite as

Pharmacokinetics of Ofloxacin in Patients on Haemodialysis Treatment

  • A. DörflerIII
  • W. Schulz
  • F. Burkharde
  • M. Zichner
Section 2: Pharmacokinetic Profile of Oxfloxacin

Summary

Serum concentrations and pharmacokinetic parameters of ofloxacin were measured in 10 patients on haemodialysis treatment. Serum half-life during the interdialytic interval was 48 hours, and during haemodialysis treatment 10 hours. The decrease in serum concentrations during a 4-hour haemodialysis was 25%. After several doses of ofloxacin, saturation of the tissues and a rediffusion of ofloxacin from the tissues during haemodialysis has to be assumed. This equalises the rate of elimination, and the serum ofloxacin concentration did not change during the last 2 hours of haemodialysis. The negative influence of phosphate binders on the resorption of ofloxacin can be confirmed.

The following ofloxacin dosage regimen is recommended in haemodialysis patients: 200mg initially, 100mg loading dose after the first haemodialysis, then 100mg daily.

Keywords

Serum Concentration Ofloxacin Phosphate Binder Dialysis Fluid Haemodialysis Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dagrosa EE, Verho M, Malerczyk V. Pharmakokinetik von Ofloxacin. Fortschritte in der Antimikrobiellen und Antineoplastischen Chemotherapie 5–5: 819–828, 1986Google Scholar
  2. Höffler D. Gyrasehemmer, Daten zur Pharmakokinetic bei Niereninsuffizienz Poster Gyrasehemmersymposium Straubing 1986Google Scholar
  3. Ichihara N, Tachizawa H, Tsumura M, Une T, Sato K. Phase I Study on DL-8280. Chemotherapy (Tokyo) 32 (Suppl. 1): 118–149, 1984Google Scholar
  4. Lode H. Discussion. Fortschritte in der Antimikrobiellen und Antineoplastischen Chemotherapie 5–5: 831, 1986Google Scholar
  5. Naber K, Bartosik-Wich B. Serum und Urinkonzentrationen von Ofloxacin, Norfloxacin und Ciprofloxacin bei älteren urologischen Patienten. Fortschritte in der Antimikrobiellen und Antineoplastischen Chemotherapie 3–5: 701–709, 1984Google Scholar
  6. Naber K, Adam D, Wittenberger R, Bartosik-Wich B. In Vitro-Aktivität, Serum-, Urin- und Prostataadenom-Gewebekonzentrationen von Ofloxacin bei nephrologischen Patienten mit komplizierten Hamwegsinfekten. Infection 14 (Suppl. 1): 60–64, 1986CrossRefGoogle Scholar
  7. Schulz W, Dörfler A. Ofloxacin-Behandlung komplizierter Hamwegsinfekte bei nephrologischen Problempatienten mit unterschiedlich ausgeprägter Niereninsuffizienz (inkl. Dialysepatienten). Infection 14 (Suppl. 1): 97–101, 1986CrossRefGoogle Scholar
  8. Verho M, Malerczyk V, Dagrosa EE, Gum A. The effect of food on pharmacokinetics of ofloxacin. Current Medical Research and Opinion 10: 166–177, 1986PubMedCrossRefGoogle Scholar
  9. Zahlten R. Klinische Erfahrungen mit Ofloxacin an 4200Patienten. Referate zur Antimikrobiellen und Antineoplastischen Chemotherapie 1–2: 71–79, 1985Google Scholar

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • A. DörflerIII
    • 1
  • W. Schulz
    • 1
  • F. Burkharde
    • 2
  • M. Zichner
    • 3
  1. 1.Klinik, Klinikum BambergLehrkrankenhaus der Universität Erlangen-NürnbergBambergGermany
  2. 2.Landesuntersuchungsanstalt für das Gesundheitswesen NordbayernErlangenGermany
  3. 3.Klinische PrüfungHoechst AGNürnbergGermany

Personalised recommendations